Bolt Biotherapeutics - BOLT Stock Forecast, Price & News

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Bolt Biotherapeutics Stock Performance

Shares of BOLT traded up $0.09 during mid-day trading on Friday, reaching $2.49. 62,626 shares of the company's stock were exchanged, compared to its average volume of 132,040. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.16 and a quick ratio of 10.16. The stock has a market capitalization of $93.30 million, a PE ratio of -0.94 and a beta of 0.99. The business's fifty day simple moving average is $2.14 and its 200-day simple moving average is $2.48. Bolt Biotherapeutics has a 52-week low of $1.39 and a 52-week high of $19.28.

Bolt Biotherapeutics (NASDAQ:BOLT - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.07. The firm had revenue of $0.81 million during the quarter, compared to analysts' expectations of $1.38 million. On average, equities research analysts expect that Bolt Biotherapeutics will post -2.87 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BOLT shares. Stifel Nicolaus dropped their price objective on shares of Bolt Biotherapeutics from $16.00 to $13.00 in a report on Friday, May 13th. Morgan Stanley dropped their price objective on shares of Bolt Biotherapeutics to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, May 17th.

Insider Buying and Selling at Bolt Biotherapeutics

In other Bolt Biotherapeutics news, major shareholder Holdings A/S Novo sold 800,000 shares of the firm's stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $2.00, for a total value of $1,600,000.00. Following the completion of the sale, the insider now owns 3,703,991 shares of the company's stock, valued at $7,407,982. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 22.90% of the stock is owned by corporate insiders.